avapro has been researched along with Liver Steatosis in 4 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin II (AII) has been shown to contribute to the pathogenesis of hypertension and insulin resistance." | 3.73 | Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. ( Argentino, DP; Dominici, FP; Muñoz, MC; Toblli, JE; Turyn, D, 2006) |
| "Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of a metabolic syndrome characterized by accumulation of hepatic fat, inflammation and varying degrees of fibrosis." | 1.38 | Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. ( Kato, J; Kishina, M; Koda, M; Matono, T; Murawaki, Y; Sugihara, T; Tokunaga, S; Ueki, M, 2012) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, J | 1 |
| Gong, W | 1 |
| Lu, L | 1 |
| Chen, J | 1 |
| Lu, Z | 1 |
| Li, H | 1 |
| Liu, W | 1 |
| Liu, Y | 1 |
| Wang, M | 1 |
| Hu, R | 1 |
| Long, H | 1 |
| Wei, L | 1 |
| Kato, J | 1 |
| Koda, M | 1 |
| Kishina, M | 1 |
| Tokunaga, S | 1 |
| Matono, T | 1 |
| Sugihara, T | 1 |
| Ueki, M | 1 |
| Murawaki, Y | 1 |
| Muñoz, MC | 2 |
| Argentino, DP | 1 |
| Dominici, FP | 1 |
| Turyn, D | 1 |
| Toblli, JE | 2 |
| Cao, G | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
4 other studies available for avapro and Liver Steatosis
| Article | Year |
|---|---|
Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Autophagy; Biphenyl Compounds; Dia | 2017 |
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Comp | 2012 |
Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Re | 2006 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |